Lexeo Therapeutics
Chemicals & Related Products · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
345 Park Ave S Fl 6, New York, New York,...Phone Number
(212) 547-9879Website
www.lexeotx.comRevenue
-Stock Symbol
LXEOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Lexeo Therapeutics
Based out of New York City, NY, Lexeo Therapeutics is a biotechnology company with a focus on genetic medicines and rare diseases. Lexeo is a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated.Explore more
Lexeo Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
HD
Vice President, Late-Stage Cardiology Develop...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lexeo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Lexeo Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Lexeo Therapeutics has new funding data
Check if Lexeo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Lexeo Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Lexeo Therapeutics
Click to see if Lexeo Therapeutics had a recent Job posting/layoffs
Lexeo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Lexeo Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Lexeo Therapeutics
Compare insights from companies similar to Lexeo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lexeo Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lexeo Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lexeo Therapeutics.
Lexeo Therapeutics financials insights
Gather financial insights about Lexeo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$85M
Series B
$100M
2023
Stock Offering
$100M
2024
Share Placement
$95M
2025
Stock/Share Issuance
$80M
Lexeo Therapeutics Tech Stack
A closer look at the technologies used by Lexeo Therapeutics
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance, Tax
Person-Based
Share Placement, Finance, Tax
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Open Position
Lexeo Therapeutics News & Media
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACMLexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia June 29, 2026 2:00 PM EDTCompany...Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studiesLexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lexeo Therapeutics
Sign Up For FreeTo access detailed company insights
Based out of New York City, NY, Lexeo Therapeutics is a biotechnology company with a focus on genetic medicines and rare diseases. Lexeo is a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated.... Read More
